Produktinformationen zu „Obstructive Airway Diseases (PDF)“
Incidences of inflammatory airway diseases are on the rise across the world. Existing therapeutic options are ineffective, unsafe, and expensive, and severe cases are nonresponsive to conventional therapy. Therefore, it is imperative that research be undertaken to discover new treatment options. Obstructive Airway Diseases: Role of Lipid Mediators discusses clinically successful and potential lipid targets that can make a difference in treating some of the most intractable disease states.Topics discussed include:Obstructive airway diseases, etiology, pathophysiology, and existing therapeutic optionsWhat constitutes a lipid and how it is broken down to generate biologically active mediatorsThe role of enzymes in the process of lipid mediator synthesisThe biology of arachidonic acid, platelet-activating factor, and lysophosphatidic acid and the role they play in airway inflammationProducts of arachidonic acid metabolism such as leukotrienes, prostaglandins, epieicosatrienoic acid, and oxoeicosatetraenoic acidProresolution lipid mediators in inflammatory airway disease conditionsThe role of sphingosine and ceramide in inflammatory airway diseaseProtein kinases activated by lipid mediators and those that trigger the generation of lipid messengersThe combined input of a panel of international authorities on lipid mediators makes this volume a valuable resource for all those involved in researching, teaching, and studying airway inflammation as well as those involved in drug discovery research.Punit Srivastava maintains a blog with additional information about the book and his work.
Autoren-Porträt
Abhijit Ray has worked in human trials with molecules designed to treat airway inflammation associated with asthma and COPD and has published more than 60 articles in peer-reviewed journals. He has been the senior director and head of biology research at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. As a member of the drug discovery team, he manages a group of 60 scientists engaged in discovery research for drugs in the areas of infectious and inflammatory diseases.
Punit Srivastava has been a group leader of biology at Daiichi Sankyo Life Science Research Centre India, Gurgaon since July 2010. He was a member of the drug discovery group of Ranbaxy Laboratories Ltd. from 2004 to June 2010 and has worked for more than six years in drug discovery research, which has resulted in one molecule entering human trial for COPD. He has published more than 15 articles in peer-reviewed journals and filed at least six patents. As a member of the drug discovery team at Daiichi Sankyo, he is leading projects in the area of inflammation.
Bibliographische Angaben
-
2016, 381 Seiten, Englisch
- Herausgegeben: Abhijit Ray, Punit Kumar Srivastava
- Verlag: Taylor & Francis
- ISBN-10: 1439851417
- ISBN-13: 9781439851418
- Erscheinungsdatum: 19.04.2016
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
-
Dateiformat: PDF
-
Größe: 10 MB
-
Mit Kopierschutz
-
Vorlesefunktion
Kopierschutz
Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.
Schreiben Sie einen Kommentar zu "Obstructive Airway Diseases".
Kommentar verfassen